Krystal Biotech Inc (KRYS)
164.41
+0.63
(+0.38%)
USD |
NASDAQ |
May 20, 16:00
164.41
0.00 (0.00%)
After-Hours: 17:39
Krystal Biotech Research and Development Expense (Quarterly): 10.96M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 10.96M |
| December 31, 2023 | 11.37M |
| September 30, 2023 | 10.63M |
| June 30, 2023 | 12.14M |
| March 31, 2023 | 12.29M |
| December 31, 2022 | 10.74M |
| September 30, 2022 | 11.52M |
| June 30, 2022 | 10.89M |
| March 31, 2022 | 9.314M |
| December 31, 2021 | 9.009M |
| September 30, 2021 | 6.08M |
| June 30, 2021 | 6.594M |
| March 31, 2021 | 6.201M |
| December 31, 2020 | 5.672M |
| September 30, 2020 | 5.10M |
| June 30, 2020 | 3.639M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.525M |
| December 31, 2019 | 4.349M |
| September 30, 2019 | 3.885M |
| June 30, 2019 | 4.216M |
| March 31, 2019 | 3.167M |
| December 31, 2018 | 2.802M |
| September 30, 2018 | 1.914M |
| June 30, 2018 | 1.525M |
| March 31, 2018 | 1.52M |
| December 31, 2017 | 1.088M |
| September 30, 2017 | 1.355M |
| June 30, 2017 | 0.446M |
| March 31, 2017 | 0.319M |
| December 31, 2016 | 0.402M |
| September 30, 2016 | 0.241M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.525M
Minimum
Mar 2020
12.29M
Maximum
Mar 2023
7.906M
Average
7.802M
Median
Research and Development Expense (Quarterly) Benchmarks
| Axsome Therapeutics Inc | 36.83M |
| Catalyst Pharmaceuticals Inc | 2.581M |
| EyePoint Pharmaceuticals Inc | 30.14M |
| Madrigal Pharmaceuticals Inc | 71.24M |
| Viking Therapeutics Inc | 24.10M |